Galiximab
Based on 1 publication(s) in Google Scholar
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.23%
- CAS. Nr.: 357613-77-5
- Molecular Weight:145.24 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Galiximab
More
Biologische Aktivität
Human IgG1 lambda
Human
CD28L/CD80
Galiximab (25-100 μg/mL; 36 h) in combination with Doxorubicin (HY-15142A) significantly enhances apoptosis in Raji cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raji cells treated Doxorubicin (HY-15142A) (0.05-1 µg/mL)
-
Concentration:25, 50 and 100 μg/mL
-
Incubation Time:36 h
-
Result:Enhanced cell apoptosis in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB17 SCID mice aged 6-8 weeks old treated Raji cells or SKW6.4 cells[1]
-
Dosage:Raji model: 0.1, 1, 3, 10, 30 mg/kg; once weekly; 3 times in total
SKW6.4 model: 5, 10, 30 mg/kg; once weekly; 4 times in total -
Administration:Intraperitoneal injection
-
Result:Showed dose-dependent tumor growth inhibition and survival prolongation in both models.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD28L/CD80 (red) with Galiximab (anti-CD28L/CD80) (HY-P99293). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS. Nr. 357613-77-5
-
Appearance Liquid
-
Molecular Weight 145.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Galiximab]
-
Synonyms
IDEC 114; Anti-Human CD80 Recombinant Antibody
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
CD80 (B7-1) as a potential therapeutic target in Epstein-Barr virus‑associated B cell diseases. [Abstract]2026 May 26. PMID: 42191836
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Hariharan K, et al. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Int J Oncol. 2013 Aug;43(2):670-6. [Content Brief]
[2]. Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405-10. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)